An interventional study of Implantable cardiac monitor implantation in Ventricular Arrhythmia, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
After myocardial infarction (MI), reduced LVEF (≤35%) is a known risk marker for sudden cardiac death (SCD), yet many SCD cases occur with LVEF >35% as myocardial scarring remains a strong arrhythmogenic substrate regardless of preserved function. Non-sustained ventricular tachycardias ((NS)VTs) predict malignant arrhythmias and highlight the importance of early detection.
The primary objective is to determine whether continuous cardiac rhythm monitoring after myocardial infarction improves the detection of cardiac arrhythmias that require medical intervention by conducting a prospective, multi-center, international, randomized trial.
After myocardial infarction (MI), reduced left ventricular ejection fraction (LVEF ≤35%) is a well-known risk factor for sudden cardiac death (SCD), but many SCD cases occur in patients with preserved or mildly reduced LVEF (>35%) due to the arrhythmogenic potential of myocardial scar tissue. Non-sustained ventricular tachycardia (NSVT) is an early marker of malignant arrhythmias, underscoring the value of continuous rhythm monitoring. This prospective, multicentre, randomized trial investigates whether continuous cardiac rhythm monitoring using an implantable loop recorder in post-MI patients with LVEF >35 ≤50% and proven myocardial scar improves detection of clinically relevant arrhythmias compared with standard care. Secondary aims include evaluating the incidence of NSVT/VT/VF, premature ventricular contraction (PVC) burden, and the prognostic value of biomarkers such as NT-proBNP, Lp(a), IL-6, and CRP, as well as assessing patient safety perception and the potential health benefits of early intervention.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 533 studies on the registry; 182 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
>35-≤50% measured > 48 hours after index STEMI or NSTEMI
o In case a candidate has an LVEF \<35% after a recent MI, the responsible physician can decide to treat the patient with GDMT first and reassess the LVEF after 3 months post-MI
myocardial scar, identified by one of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing an ICM implant for continuous cardiac monitoring
Device: Implantable cardiac monitor implantation
Control group with standard of care without ICM implant
Implantable cardiac monitor implantation for continuous monitoring
Time to first documented cardiac arrhythmia prompting medical intervention
Composite endpoint defined as the first documented cardiac arrhythmia that prompts a clinical action, including a change in medication, a diagnostic or interventional procedure, or hospitalization. Each participant contributes only their first qualifying event, regardless of arrhythmia type or clinical action. The outcome will be reported as the cumulative incidence of this composite event, expressed as a percentage, and compared between the insertable cardiac monitor (ICM) and standard-care groups using time-to-event analysis.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants with non-sustained ventricular tachycardia, ventricular tachycardia, or ventricular fibrillation
Composite endpoint comprising documented non-sustained ventricular tachycardia (NSVT), ventricular tachycardia (VT), or ventricular fibrillation (VF). A participant meets the endpoint upon documentation of any component and is counted once, even if multiple components or episodes occur. Medical intervention is not required. Counts will be compared between study groups.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants who die from any cause
Number of participants who die from any cause during follow-up, compared between the ICM and standard-care groups.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants who die from a cardiovascular cause
Number of participants who die as a result of a cardiovascular complication, as defined in the protocol, compared between the ICM and standard-care groups.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants with a documented cardiac arrhythmia
Composite endpoint comprising documented cardiac arrhythmias as defined in the protocol. A participant is counted once upon documentation of any qualifying arrhythmia, regardless of the number or type of subsequent arrhythmias. Medical intervention is not required. Counts will be compared between study groups.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants with documented bradycardia
Number of participants with at least one documented episode of bradycardia meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether bradycardia prompts medical intervention.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants with documented sinus node dysfunction
Number of participants with documented sinus node dysfunction. Each participant is counted once. Counts will be reported by study group and according to whether sinus node dysfunction prompts medical intervention.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants with documented atrioventricular block
Number of participants with documented atrioventricular block, classified using the protocol definitions. Each participant is counted once. Counts will be reported by study group and according to whether atrioventricular block prompts medical intervention.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants with documented atrial fibrillation
Number of participants with documented atrial fibrillation meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether atrial fibrillation prompts medical intervention.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants with documented supraventricular tachycardia other than atrial fibrillation
Number of participants with documented supraventricular tachycardia other than atrial fibrillation, classified using the protocol definitions. Each participant is counted once. Counts will be reported by study group and according to whether the arrhythmia prompts medical intervention.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants with documented non-sustained ventricular tachycardia
Number of participants with documented non-sustained ventricular tachycardia (NSVT) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether NSVT prompts medical intervention.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants with documented ventricular tachycardia
Number of participants with documented ventricular tachycardia (VT) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether VT prompts medical intervention.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants with documented ventricular fibrillation
Number of participants with documented ventricular fibrillation (VF) meeting the protocol definition. Each participant is counted once. Counts will be reported by study group and according to whether VF prompts medical intervention.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants receiving invasive interventions for cardiac arrhythmias
Number of participants receiving at least one invasive clinical intervention for a documented cardiac arrhythmia. Each participant is counted once, regardless of the number of invasive interventions received. Counts will be compared between study groups.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants with supraventricular arrhythmias necessitating clinical intervention
Number of participants with at least one documented supraventricular arrhythmia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants with bradycardia necessitating clinical intervention
Number of participants with at least one documented episode of bradycardia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants with ventricular arrhythmias necessitating clinical intervention
Number of participants with at least one documented ventricular arrhythmia that prompts clinical intervention. Each participant is counted once. Counts will be compared between the ICM and standard-care groups.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants receiving an implantable cardioverter-defibrillator
Number of participants undergoing implantable cardioverter-defibrillator (ICD) implantation during follow-up. Each participant is counted once. Counts will be compared between study groups.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants receiving a pacemaker
Number of participants undergoing pacemaker implantation during follow-up. Each participant is counted once. Counts will be compared between study groups.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants receiving appropriate implantable cardioverter-defibrillator therapy
Number of participants receiving at least one appropriate implantable cardioverter-defibrillator (ICD) therapy after ICD implantation. Each participant is counted once, regardless of the number of appropriate therapies received.
Time frame: From ICD implantation through the end of the planned 36-month participant follow-up period.
Number of participants with complications related to insertable cardiac monitor implantation
Number of participants in the ICM group experiencing at least one complication related to ICM implantation, including implantation-site infection, hematoma, or device migration. Each participant is counted once. Complication types will be reported as categories of the same participant-count measure.
Time frame: From ICM implantation through the end of ICM follow-up, anticipated to last 36 months after implantation.
Number of participants with suspected serious complications related to arrhythmia-directed clinical interventions
Number of participants experiencing at least one suspected serious complication related to a clinical intervention performed for a detected cardiac arrhythmia. Each participant is counted once. Complication types will be reported as categories of the same participant-count measure.
Time frame: Throughout the planned 36-month participant follow-up period.
Number of participants meeting the composite health-risk endpoint
Composite endpoint comprising an increase of at least one NYHA class, heart failure admission, cardiovascular death, percutaneous coronary intervention, myocardial infarction, cerebrovascular accident, coronary artery bypass grafting, or valve surgery. A participant meets the endpoint if any component occurs and is counted once, regardless of the number of components experienced. Counts will be compared between study groups.
Time frame: Clinical events throughout the planned 36-month follow-up period; NYHA class assessed at baseline and 12, 24, and 36 months.
Percentage of participants with documented non-sustained ventricular tachycardia
Percentage of participants in the insertable cardiac monitor (ICM) group with at least one adjudicated non-sustained ventricular tachycardia (NSVT) episode during each assessment window. Each participant is counted once per window, regardless of the number of episodes. The percentage is calculated as the number of participants with NSVT divided by the number of participants in the analysis population, multiplied by 100. The numerator and denominator will also be reported.
Time frame: During the first 30 days and first 6 months after initiation of LUX monitoring.
Rate of non-sustained ventricular tachycardia episodes per monitoring day
Rate of all adjudicated non-sustained ventricular tachycardia (NSVT) episodes recorded by the insertable cardiac monitor (ICM). All qualifying episodes are counted, including recurrent episodes within the same participant. For each assessment window, the rate is calculated as the total number of NSVT episodes across participants in the ICM group divided by their total observed ICM monitoring time in days. NSVT is classified according to the protocol definition.
Time frame: During the first 30 days and first 6 months after initiation of LUX monitoring.
Percentage of participants with documented sustained ventricular tachycardia
Percentage of participants in the ICM group with at least one adjudicated sustained ventricular tachycardia (VT) episode during each assessment window. Each participant is counted once per window. The percentage is calculated as the number of participants with sustained VT divided by the number of participants in the analysis population, multiplied by 100. The numerator and denominator will also be reported.
Time frame: During the first 30 days and first 6 months after initiation of LUX monitoring.
Rate of documented sustained ventricular tachycardia episodes per monitoring day
Rate of all adjudicated sustained VT episodes recorded by the ICM, including recurrent episodes within the same participant. For each assessment window, the rate is calculated as the total number of sustained VT episodes across participants in the ICM group divided by their total observed ICM monitoring time in days. Results are expressed as sustained VT episodes per monitoring day.
Time frame: During the first 30 days and first 6 months after initiation of LUX monitoring
Percentage of participants meeting the early composite PVC, NSVT, VT, or VF endpoin
Percentage of participants meeting a composite endpoint comprising PVC, NSVT, sustained VT, or ventricular fibrillation (VF). A participant meets the endpoint if any component occurs and is counted once per assessment window. The percentage is calculated as the number of qualifying participants divided by the number in the analysis population, multiplied by 100, and compared between study groups.
Time frame: During the first 30 days and first 6 months of participant follow-up.
Rate of events meeting the early composite PVC, NSVT, VT, or VF endpoint
Rate of events meeting the composite endpoint comprising PVC, NSVT, sustained VT, or VF. Qualifying events will be counted according to protocol description and divided by time of follow-up. Results will be compared between study groups.
Time frame: During the first 30 days and first 6 months of participant follow-up.
Mean premature ventricular contraction burden
Mean premature ventricular contraction (PVC) burden recorded by the ICM in the ICM group. For each participant, daily device-recorded PVC burden, expressed as a percentage, will be averaged over the observation period. The participant-level averages will then be summarized as the group mean PVC burden
Time frame: Throughout ICM monitoring, anticipated to last 36 months after implantation.
Change from baseline in EQ-5D-5L score
Health status assessed using the EQ-5D-5L specific score. Changes from baseline will be calculated at 12, 24, and 36 months and compared between the ICM and standard-care groups to assess differences in change over time. There is also an visual analogue sclae with scores that ranges from 0 to 100, with higher scores indicating better perception of being healthy. Changes will be summarized using these scores
Time frame: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
Change from baseline in self-assessed NYHA class
Functional status assessed using self-assessed New York Heart Association (NYHA) class. Changes from baseline will be determined at 12, 24, and 36 months and compared between the ICM and standard-care groups. Changes will be reported as NYHA class. Higher NYHA classes indicate greater functional limitation.
Time frame: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
Change from the initial post-implant assessment in Florida Patient Acceptance Survey using the FPAS specific score
Device acceptance assessed using the Florida Patient Acceptance Survey (FPAS) in the ICM group only. Changes from the initial post-implant assessment will be calculated at 12, 24, and 36 months to assess change over time. The score ranges from 0 to 100, with higher scores indicating better acceptance.
Time frame: Baseline and 12, 24, and 36 months. Follow-up questionnaires are completed within 1 month of each scheduled assessment.
NT-proBNP concentration
NT-proBNP concentration measured in blood samples and expressed in ng/L. Baseline concentrations will be evaluated as a predictor of cardiac arrhythmias. Follow-up concentrations will be collected only when measured during routine clinical care.
Time frame: Baseline: within 6 months before enrollment and after the most recent MI. Additional routine-care measurements throughout the planned 36-month follow-up.
Mean daily coffee intake assessed using the study questionnaire
Participant-reported coffee intake assessed using the additional study questionnaire and expressed as cups per day. The mean number of cups consumed per day will be calculated across participants with available questionnaire responses at each assessment.
Time frame: At baseline, 12-, 24-, and 36 months
Mean weekly alcohol intake assessed using the study questionnaire
Participant-reported alcohol intake assessed using the additional study questionnaire and expressed as standard drinks per week. Mean weekly intake will be calculated across participants with available questionnaire responses at each assessment.
Time frame: At baseline, 12-, 24-, and 36 months
Started Apr 2026 (actual). Primary completion is estimated for Apr 2030, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) →